Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Soraprazan - Katairo

Drug Profile

Soraprazan - Katairo

Alternative Names: BY-359; BYK-61359; Remofuscin

Latest Information Update: 28 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ALTANA Pharma
  • Developer ALTANA Pharma; Katairo
  • Class Antiulcers; Eye disorder therapies; Imidazoles; Naphthyridines
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stargardt disease
  • New Molecular Entity No

Highest Development Phases

  • Phase II Stargardt disease
  • No development reported Dry age-related macular degeneration
  • Discontinued Gastro-oesophageal reflux

Most Recent Events

  • 28 Jun 2022 No recent reports of development identified for phase-I development in Dry age-related macular degeneration in Germany (PO, Tablet)
  • 30 May 2019 Phase-I clinical trials in Dry age-related macular degeneration in Germany (PO) (Katairo Pipeline, May 2019)
  • 09 May 2019 Phase-II clinical trials in Stargardt disease in United Kingdom, Italy, Germany (PO) (EudraCT2018-001496-20)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top